glp-1 mounjaro use tripled among non-diabetics, reaching $5.8B in 2022 As Ozempic and Mounjaro reshape

Weight-Loss Drug Maridebart Cafraglutide Shows Efficacy in Phase 2 Trial AJMC Once-Monthly Obesity Medication Shows Promise Yale School of Medicine The Latest Updates: 16 New Weight Loss Drugs on the Horizon GoodRx Oral, Subcutaneous Amycretin Similarly Safe, Tolerated as GLP-1 ACC Madrigal Pharmaceuticals Enters Exclusive Global License Agreement for Oral GLP-1 Madrigal Pharmaceuticals GLP-1 Weight Loss Provider Tips Keep abreast of trial outcomes and anticipated FDA approvals for new agents

Growing Use Cases: Recent clinical trials have shown that GLP-1RAs can also support reducing cardiovascular risk and heart failure-related symptoms and slow down the progression of kidney diseases

You do not need an elaborate program

Of those that dont currently cover the drugs for weight loss, 54% say theyre unlikely to do so soon, while just 6% are likely to add coverage in the near term

These drugs improve glucose control, reduce weight, and lower cardiovascular risk

daily) Other health conditions that could affect your safety or suitability for treatment Cost and insurance coverage, which can vary greatly between drugs While semaglutide and tirzepatide generally show the highest average weight loss in trials, liraglutide may still be the better choice for certain patients